Research programme: deimmunized therapeutic proteins - Insmed
Latest Information Update: 18 May 2023
At a glance
- Originator Insmed
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 15 May 2023 Preclinical trials in Unspecified in USA (Parenteral) prior to May 2023 (Insmed pipeline, May 2023)